Table 4

Studies of the effects of angiotensin II receptor antagonists on portal pressure

Author/year No patients Drug dose (mg) Duration WHVP (mm Hg) FHVP (mm Hg) HPVG (mm Hg) MAP (mm Hg)
Arroyo, 198145 14Saralasin 1–2.5 mg/kg/minSingle infusion17.2 (0.9) to 13.7 (0.9)4-150 NANA76.8 (4) to 61.1 (5.9)4-150
Schneider, 199920 30 (HVPG ⩾20
mm Hg)
Losartan 25 mg1 week29.5 (3.8) to 18 (4.8)4-150 4.8 (2.2) to 4.8 (2.4)24.8 (2.6) to 13.1 (4.1)4-150 89.1 (6.8) to 86 (7.8)4-150
15 (HVPG ⩾20
mm Hg)
Placebo1 week28.8 (3.3) to 27.9 (3.8)4.9 (2.2) to 4.8 (2.1)23.9 (4.1) to 23.1 (4.2)88.3 (5.5) to 88.6 (4.5)
15 (HVPG <20
mm Hg)
Losartan 25 mg 1 week22.1 (2. 6) to 14.1 (2.9)4-150 4.2 (1.6) to 4.1 (1.5)17.9 (1.4) to 10 (2.7)4-150 90.9 (5.5) to 87.4 (4.6)4-150
10 (HVPG <20
mm Hg)
Placebo1 week17.7 (1.3) to 16.9 (1.5)4.3 (1.9) to 4.5 (1.9)17.7 (1.3) to 16.9 (1.5)93.3 (6.7) to 91.7 (4.5)
Debernardi-Venon, 199921 114-154 Irbesartan 300 mg8 weeksNANA18.3 (4) to 14.5 (3.4)4-150 NA
Schepke, 200049 144-153 Irbesartan 150 mg1 weekNANA18.3 (4) to 14.7 (3.7)4-150 81.3 (16) to 76.7 (14.7)
16Placebo1 weekNANA18 (3.9) to 17.6 (3.6)81.8 (8.6) to 87.1 (9.9)
  • Values are mean (SD).

  • NA, data not available; WHVP, wedged hepatic venous pressure; FHVP, free hepatic venous pressure; HVPG, hepatic venous pressure gradient; MAP, mean arterial pressure.

  • 4-150 Statistically significant.

  • 4-154 One stopped due to side effects.

  • 4-153 Four stopped due to side effects.